Latest Articlesddd
Le CompaGnon Part 1 TUESDAY June 14, 2016 The Eternal Market Games Unfortunately, the fabrication and …
Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration …
Prohost Letter #396 CELEBRATING MEMORIAL DAY - Wish you celebrated the Memorial Day. Memorial Day’s purpose was …
Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for …
Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 …
Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from …
Ionis Pharmaceuticals (IONS) stock plummeted when GlaxoSmithKline (GSK) stopped pursuing a late stage trial of Ionis-TTR …
GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …
Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ …
CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance …
Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have …
COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm …
Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief …
Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of …
GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent …
By June, which is next month, Incyte (INCY) will be the owner of the European operations …
EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …
Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy …
GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …
Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
